Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MACROGENICS INCMGNX · Entity 6104 | Senior VP, GC, and Secretary | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MACROGENICS INC
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 31,105 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2026. F2: This transaction was executed in multiple trades at prices ranging from $4.12 to $4.24. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $4.12 to $4.24. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 20, 2026 22:19 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 31,105 | $4.15 | $129,085.75 |
DisclosureSEC source: 0001706903-26-000006 · wk-form4_1787264339.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.12 to $4.24. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 15, 2026 Filed Feb 17, 2026 23:25 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 13,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001706903-26-000004 · wk-form4_1771370708.xml · derivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2026 Filed Feb 17, 2026 23:25 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 5,147 | $1.71 | $8,801.37 |
DisclosureSEC source: 0001706903-26-000004 · wk-form4_1771370708.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,105 Read SEC document |
| February 15, 2026 Filed Feb 17, 2026 23:25 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 13,332 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001706903-26-000004 · wk-form4_1771370708.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 23:25 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001706903-26-000004 · wk-form4_1771370708.xml · derivative · entry 5 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 23:25 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001706903-26-000004 · wk-form4_1771370708.xml · derivative · entry 4 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-12 F2 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 08, 2026 Filed Feb 10, 2026 23:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 8,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001706903-26-000002 · wk-form4_1770765298.xml · derivative · entry 6 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 8,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into the Company's stock on a one-for-one basis. F3 · derivative.exercise_date: On February 8, 2024, the reporting person was granted 27,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On February 8, 2024, the reporting person was granted 27,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 08, 2026 Filed Feb 10, 2026 23:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 3,474 | $1.81 | $6,287.94 |
DisclosureSEC source: 0001706903-26-000002 · wk-form4_1770765298.xml · nonDerivative · entry 4 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,920 Read SEC document |
| February 08, 2026 Filed Feb 10, 2026 23:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 8,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001706903-26-000002 · wk-form4_1770765298.xml · nonDerivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 23:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 6,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001706903-26-000002 · wk-form4_1770765298.xml · derivative · entry 5 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,999 Underlying: Common Stock · 6,001 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into the Company's stock on a one-for-one basis. F2 · derivative.exercise_date: On February 7, 2025, the reporting person was granted 18,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date F2 · derivative.expiration_date: On February 7, 2025, the reporting person was granted 18,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 23:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 2,317 | $1.81 | $4,193.77 |
DisclosureSEC source: 0001706903-26-000002 · wk-form4_1770765298.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,395 Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 23:15 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 6,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001706903-26-000002 · wk-form4_1770765298.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP, GC, and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:12 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001706903-25-000003 · wk-form4_1755634329.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-08-15 F1 · derivative.exercise_date: 25% of the options will vest and become exercisable one year after the grant date and the remaining 75% will vest in 12 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:25 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 13,332 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000033 · wk-form4_1740000341.xml · derivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,332 Underlying: Common Stock · 13,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:25 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 5,147 | $2.56 | $13,176.32 |
DisclosureSEC source: 0001125345-25-000033 · wk-form4_1740000341.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,711 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:25 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 13,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000033 · wk-form4_1740000341.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 9,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000012 · wk-form4_1739323154.xml · derivative · entry 5 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,999 Underlying: Common Stock · 9,001 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 8, 2024, the reporting person was granted 27,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 8, 2024, the reporting person was granted 27,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 8, 2024, the reporting person was granted 27,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 3,475 | $2.60 | $9,035.00 |
DisclosureSEC source: 0001125345-25-000012 · wk-form4_1739323154.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,526 Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 9,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-25-000012 · wk-form4_1739323154.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 8, 2024, the reporting person was granted 27,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 01:19 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000012 · wk-form4_1739323154.xml · derivative · entry 4 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 01:19 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001125345-25-000012 · wk-form4_1739323154.xml · derivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2035-02-07 F2 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:07 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 42,500 | $4.82 Strike: $4.82 | $204,850.00 |
DisclosureSEC source: 0001125345-24-000079 · wk-form4_1712614042.xml · derivative · entry 7 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 42,500 shares Expires 2033-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023. F6 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the 2/15/2023 date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:07 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 3,165 | $18.22 | $57,666.30 |
DisclosureSEC source: 0001125345-24-000079 · wk-form4_1712614042.xml · nonDerivative · entry 6 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $18.00 to $18.84. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:07 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 5,351 | $17.74 | $94,926.74 |
DisclosureSEC source: 0001125345-24-000079 · wk-form4_1712614042.xml · nonDerivative · entry 5 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,165 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $17.05 to $17.99. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:07 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 232 | $16.38 | $3,800.16 |
DisclosureSEC source: 0001125345-24-000079 · wk-form4_1712614042.xml · nonDerivative · entry 4 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,516 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.01 to $16.58. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:07 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 147 | $15.51 | $2,279.97 |
DisclosureSEC source: 0001125345-24-000079 · wk-form4_1712614042.xml · nonDerivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,748 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.07 to $15.94. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:07 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 42,500 | $15.07 | $640,475.00 |
DisclosureSEC source: 0001125345-24-000079 · wk-form4_1712614042.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:07 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 42,500 | $4.82 | $204,850.00 |
DisclosureSEC source: 0001125345-24-000079 · wk-form4_1712614042.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:14 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 8,750 | $10.15 Strike: $10.15 | $88,812.50 |
DisclosureSEC source: 0001125345-24-000063 · wk-form4_1709932476.xml · derivative · entry 5 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 8,750 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:14 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,875 | $11.50 Strike: $11.50 | $125,062.50 |
DisclosureSEC source: 0001125345-24-000063 · wk-form4_1709932476.xml · derivative · entry 4 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,875 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:14 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 19,625 | $21.50 | $421,937.50 |
DisclosureSEC source: 0001125345-24-000063 · wk-form4_1709932476.xml · nonDerivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,895 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:14 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 8,750 | $10.15 | $88,812.50 |
DisclosureSEC source: 0001125345-24-000063 · wk-form4_1709932476.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:14 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 10,875 | $11.50 | $125,062.50 |
DisclosureSEC source: 0001125345-24-000063 · wk-form4_1709932476.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:20 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 16,124 | $17.22 | $277,655.28 |
DisclosureSEC source: 0001125345-24-000049 · wk-form4_1709155207.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.57 to $18.37. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:27 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 26,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000047 · wk-form4_1708982859.xml · derivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% on February 22, 2024. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% on February 22, 2024. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% on February 22, 2024. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:27 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 10,126 | $17.11 | $173,255.86 |
DisclosureSEC source: 0001125345-24-000047 · wk-form4_1708982859.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,019 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:27 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000047 · wk-form4_1708982859.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% on February 22, 2024. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 13,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000041 · wk-form4_1708470299.xml · derivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,664 Underlying: Common Stock · 13,336 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 4,441 | $17.40 | $77,273.40 |
DisclosureSEC source: 0001125345-24-000041 · wk-form4_1708470299.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,895 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 13,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000041 · wk-form4_1708470299.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:32 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000020 · wk-form4_1707777115.xml · derivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:32 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 71,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001125345-24-000020 · wk-form4_1707777115.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:17 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 21,875 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001125345-24-000007 · wk-form4_1707340620.xml · derivative · entry 6 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,125 Underlying: Common Stock · 21,875 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:17 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 54,376 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001125345-24-000007 · wk-form4_1707340620.xml · derivative · entry 5 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,875 Underlying: Common Stock · 54,376 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:17 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 21,875 | $16.50 | $360,937.50 |
DisclosureSEC source: 0001125345-24-000007 · wk-form4_1707340620.xml · nonDerivative · entry 4 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:17 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 54,376 | $16.50 | $897,204.00 |
DisclosureSEC source: 0001125345-24-000007 · wk-form4_1707340620.xml · nonDerivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,875 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:17 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 21,875 | $10.15 | $222,031.25 |
DisclosureSEC source: 0001125345-24-000007 · wk-form4_1707340620.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:17 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 54,376 | $11.50 | $625,324.00 |
DisclosureSEC source: 0001125345-24-000007 · wk-form4_1707340620.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 5,372 | $6.03 | $32,393.16 |
DisclosureSEC source: 0001125345-23-000054 · wf-form4_167882533470011.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $5.80 to $6.18. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:35 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 8,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000041 · wf-form4_167727448264875.xml · derivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.